Suppr超能文献

血管内皮生长因子抑制脂多糖诱导的树突状细胞成熟,但不抑制促炎细胞因子诱导的树突状细胞成熟。

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.

作者信息

Takahashi Akihiro, Kono Koji, Ichihara Fumiko, Sugai Hidemitsu, Fujii Hideki, Matsumoto Yoshiro

机构信息

First Department of Surgery, University of Yamanashi, 1110 Shimokato, 409-3898 Tamaho, Yamanashi, Japan.

出版信息

Cancer Immunol Immunother. 2004 Jun;53(6):543-50. doi: 10.1007/s00262-003-0466-8. Epub 2003 Dec 10.

Abstract

PURPOSE

Dendritic cells (DCs) play an important role in the host's immunosurveillance against cancer. It has been shown that the function of DCs is impaired and their population decreased in a cancer-bearing host. In the present study, we investigated the mechanism of down-regulation of DCs in a cancer-bearing host.

METHODS

We evaluated the relationship between DC infiltration and production of vascular endothelial growth factor (VEGF) in carcinoma tissue by immunohistochemistry. Furthermore, functional and phenotypical alterations of DCs were evaluated when monocyte-derived, mature DCs were treated with VEGF in vitro. Monocyte-derived DCs were generated in a culture of monocyte with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor, and the maturation of DCs was induced by either lipopolysaccharide (LPS) or a proinflammatory cytokine cocktail: tumor-necrosis factor alpha, prostaglandin E2, IL-6, and IL-1beta.

RESULTS

A significant inverse correlation was found between the density of DCs and the quantity of VEGF production in gastric carcinoma tissue (r=-0.39, p<0.05). In LPS-induced maturation, the ability of mature DCs to stimulate allogenic T cells and produce IL-12 (p70 heterodimer) was suppressed by the addition of VEGF in a dose-dependent manner. A lesser expression of costimulatory molecules (CD80 and CD86) was seen in DCs treated with exogenous VEGF than in DCs not treated with VEGF. The population of dead DCs (early and late apoptosis) treated with VEGF increased more than that without VEGF treatment, using the annexin V and propidium iodide evaluation in DCs matured by LPS. In contrast, in DCs matured by the proinflammatory cytokine cocktail, the down-regulation of costimulatory molecules and induction of DC apoptosis was not seen.

CONCLUSIONS

These findings show that the inhibition of DC maturation by VEGF differs depending on the maturation status of the DCs.

摘要

目的

树突状细胞(DCs)在宿主对癌症的免疫监视中发挥重要作用。研究表明,在荷癌宿主中DCs的功能受损且其数量减少。在本研究中,我们调查了荷癌宿主中DCs下调的机制。

方法

我们通过免疫组织化学评估了癌组织中DC浸润与血管内皮生长因子(VEGF)产生之间的关系。此外,当体外将单核细胞来源的成熟DCs用VEGF处理时,评估了DCs的功能和表型改变。单核细胞来源的DCs在单核细胞与白细胞介素4(IL-4)和粒细胞-巨噬细胞集落刺激因子的培养物中产生,并且DCs的成熟由脂多糖(LPS)或促炎细胞因子混合物诱导:肿瘤坏死因子α、前列腺素E2、IL-6和IL-1β。

结果

在胃癌组织中发现DCs密度与VEGF产生量之间存在显著负相关(r = -0.39,p < 0.05)。在LPS诱导的成熟过程中,添加VEGF以剂量依赖方式抑制了成熟DCs刺激同种异体T细胞和产生IL-12(p70异二聚体)的能力。与未用VEGF处理的DCs相比,用外源性VEGF处理的DCs中协同刺激分子(CD80和CD86)的表达较低。使用膜联蛋白V和碘化丙啶评估LPS成熟的DCs,用VEGF处理的死亡DCs(早期和晚期凋亡)群体比未用VEGF处理的增加更多。相反,在由促炎细胞因子混合物成熟的DCs中,未观察到协同刺激分子的下调和DC凋亡的诱导。

结论

这些发现表明,VEGF对DC成熟的抑制因DCs的成熟状态而异。

相似文献

1
Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines.
Cancer Immunol Immunother. 2004 Jun;53(6):543-50. doi: 10.1007/s00262-003-0466-8. Epub 2003 Dec 10.
2
Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.
Cancer Immunol Immunother. 2007 Jun;56(6):761-70. doi: 10.1007/s00262-006-0234-7. Epub 2006 Nov 4.
5
Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use.
Cancer Immunol Immunother. 2001 Oct;50(8):417-27. doi: 10.1007/s002620100215.
8
IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells.
J Leukoc Biol. 2006 Jun;79(6):1279-85. doi: 10.1189/jlb.0905503. Epub 2006 Mar 21.
10
Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells.
Int Immunol. 2004 Dec;16(12):1701-9. doi: 10.1093/intimm/dxh171. Epub 2004 Oct 11.

引用本文的文献

1
Targeting myeloid cells to improve cancer immune therapy.
Front Immunol. 2025 Jul 31;16:1623436. doi: 10.3389/fimmu.2025.1623436. eCollection 2025.
2
Impact of Chitosan Nanoparticles-Coated Dendritic Cell-Based Vaccine as Cancer Immunotherapy.
Vaccines (Basel). 2025 Apr 28;13(5):474. doi: 10.3390/vaccines13050474.
3
Exploiting innate immunity for cancer immunotherapy.
Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w.
4
Dendritic cell subsets in cancer immunity and tumor antigen sensing.
Cell Mol Immunol. 2023 May;20(5):432-447. doi: 10.1038/s41423-023-00990-6. Epub 2023 Mar 22.
5
Understanding the squamous cell carcinoma immune microenvironment.
Front Immunol. 2023 Jan 30;14:1084873. doi: 10.3389/fimmu.2023.1084873. eCollection 2023.
6
Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy.
Cancer Immunol Immunother. 2023 Jun;72(6):1343-1353. doi: 10.1007/s00262-022-03333-y. Epub 2022 Nov 28.
7
Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.
Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18.
8
Immunotherapy use in oesophagogastric cancers-a review of the literature.
Br J Cancer. 2022 Jul;127(1):21-29. doi: 10.1038/s41416-022-01751-4. Epub 2022 Mar 8.
9
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
Exp Suppl. 2022;113:1-57. doi: 10.1007/978-3-030-91311-3_1.

本文引用的文献

3
VEGF as a mediator of tumor-associated immunodeficiency.
Immunol Res. 2001;23(2-3):263-72. doi: 10.1385/IR:23:2-3:263.
6
Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells.
J Immunol. 2000 Feb 1;164(3):1269-76. doi: 10.4049/jimmunol.164.3.1269.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验